Security
Akari Therapeutics plc ADS · AKTX
AKTXNASDAQotherCurrentCIK 1541157Updated Nov 2, 2026
Name history
Celsus Therapeutics Plc. · through Sep 15, 2015Morria Biopharmaceuticals PLC · through Jun 20, 2013
AKTX price & chart
Loading TradingView…
NASDAQ:AKTX on TradingView ↗About the company
We are an oncology company developing next-generation antibody-drug conjugates, or ADCs, designed around novel proprietary cancer-killing toxins, or payloads. We believe these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development.
In the news
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 ↗
Recent filings
S-8 filing
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
4 filing
DEF 14A filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 45,376,000Source | 2,734,000Source | 38,624,000Source | 50,911,000Source | 5,076,000Source | 33,889,000Source | 50,959,000Source | 2,772,000Source | 47,892,000Source | 50,562,000Source | 4,355,000Source | 13,831,612Source |
| Property, Plant and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| GoodwillUSD | 8,430,000Source | — | — | 8,430,000Source | — | — | 8,430,000Source | — | 8,430,000Source | 8,430,000Source | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 14,000Source | 16,880Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 2,246,000Source | 7,694,000Source | 2,711,000Source | 4,177,000Source | 2,768,000Source | 2,582,000Source | 1,310,000Source | 0Source | 2,599,000Source | 3,845,000Source | 13,249,945Source |
| Assets, CurrentUSD | 2,946,000Source | 2,734,000Source | 8,324,000Source | 3,301,000Source | 5,076,000Source | 3,589,000Source | 3,349,000Source | 2,772,000Source | 5,462,000Source | 2,952,000Source | 4,341,000Source | 13,814,732Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 22,689,000Source | — | 20,029,000Source | 25,306,000Source | — | 19,509,000Source | 29,213,000Source | — | 19,564,000Source | 28,333,000Source | 4,584,000Source | 12,040,866Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 6,523,000Source | 2,430,000Source | 1,000Source | 6,523,000Source | 2,430,000Source | — | 5,776,000Source | 1,598,000Source | — | 5,319,000Source | 1,324,000Source | 744,492Source |
| Additional Paid in CapitalUSD | 224,366,000Source | — | 243,759,000Source | 220,846,000Source | — | 234,811,000Source | — | — | 234,318,000Source | — | — | — |
| Retained Earnings (Accumulated Deficit)USD | -259,252,000Source | -243,480,000Source | -283,812,000Source | -252,852,000Source | -240,585,000Source | -279,005,000Source | -250,957,000Source | -233,027,000Source | -264,550,000Source | -247,252,000Source | -227,461,000Source | -217,453,110Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,144,000Source | -926,000Source | -695,000Source | -1,106,000Source | -749,000Source | -768,000Source | -773,000Source | -761,000Source | -782,000Source | -738,000Source | -1,040,000Source | -770,839Source |
| Stockholders' Equity Attributable to ParentUSD | 22,687,000Source | -6,694,000Source | 18,595,000Source | 25,605,000Source | -3,703,000Source | 14,380,000Source | 21,746,000Source | -3,553,000Source | 28,328,000Source | 22,229,000Source | -229,000Source | 1,790,746Source |
| Additional Paid in Capital, Common StockUSD | — | 183,088,000Source | — | — | 183,007,000Source | — | 215,506,000Source | 176,443,000Source | — | 212,706,000Source | 174,754,000Source | 167,076,392Source |
| Liabilities and EquityUSD | 45,376,000Source | 2,734,000Source | 38,624,000Source | 50,911,000Source | 5,076,000Source | 33,889,000Source | 50,959,000Source | 2,772,000Source | 47,892,000Source | 50,562,000Source | 4,355,000Source | 13,831,612Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 15,568,000Source | 9,428,000Source | 13,935,000Source | 17,138,000Source | 8,779,000Source | 13,415,000Source | 20,907,000Source | 6,325,000Source | 12,351,000Source | 19,910,000Source | — | — |
| Accounts Payable, CurrentUSD | 10,844,000Source | 4,782,000Source | 9,401,000Source | 11,607,000Source | 4,686,000Source | 8,641,000Source | 13,067,000Source | 3,208,000Source | 8,770,000Source | 12,407,000Source | 1,671,000Source | 946,658Source |
| Deferred Income Tax Liabilities, NetUSD | 6,952,000Source | — | 6,094,000Source | 8,040,000Source | — | 6,094,000Source | 8,040,000Source | — | 6,952,000Source | 8,040,000Source | — | — |
| Other Liabilities, NoncurrentUSD | 69,000Source | — | — | 128,000Source | — | — | 266,000Source | — | 31,000Source | 383,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,623,000Source | 2,605,000Source | 3,513,000Source | 2,468,000Source | 1,685,000Source | 3,328,000Source | 3,494,000Source | 1,530,000Source | 2,342,000Source | 3,137,000Source | 1,566,000Source | 3,148,090Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 6,952,000Source | 8,040,000Source | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | — | 14,000Source | 4,000Source | 3,708Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 305,000Source | 1,015,000Source | 2,890,000Source | 2,245,000Source | 1,150,000Source | 735,107Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | -859,000Source | — | -1,088,000Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,488,000Source | -2,150,000Source | -10,568,000Source | -12,552,000Source | -16,432,000Source | -21,504,522Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 382,000Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 53,000Source | 2,133,000Source | 13,171,000Source | 10,988,000Source | 7,020,000Source | 25,288,109Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -2,435,000Source | -17,000Source | 2,604,000Source | -1,186,000Source | -9,405,000Source | 3,888,675Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 2,544,000Source | 2,246,000Source | 7,754,000Source | 2,771,000Source | 2,828,000Source | 2,642,000Source | 5,263,000Source | 2,659,000Source | 3,845,000Source | 13,249,945Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 6,000Source | 7,000Source | 101,000Source | 143,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | 1,000Source | -4,000Source | 7,000Source | 105,088Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 685,000Source | 248,000Source | 711,000Source | 719,000Source | 305,000Source | 1,015,000Source | 2,890,000Source | 2,245,000Source | 1,150,000Source | 735,107Source |
| Amortization of Debt Issuance CostsUSD | — | — | 100,000Source | — | — | — | — | — | 100,000Source | — | — | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | 500,000Source | — | — | — |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | -100,000Source | — | — | — | — | — | -230,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | 15,000Source | 27,000Source | 99,000Source | — | 255,000Source | 334,168Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | 76,000Source | 68,000Source | -26,000Source | -50,000Source | 64,000Source | -125,000Source | -443,000Source | 6,000Source | 136,000Source | 452,664Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | — | — | — | -255,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | -967,000Source | — | — | — | — | 54,000Source | -3,164,000Source | — | — | — |
| GoodwillUSD | — | — | 8,430,000Source | — | — | 8,430,000Source | — | 8,430,000Source | 8,430,000Source | 8,430,000Source | — | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 8,430,000Source | — | 0Source | — | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | 3,700,000Source | — | 5,180,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | -1,088,000Source | — | — | 0Source | -859,000Source | 0Source | -1,003,000Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 121,000Source | 69,000Source | 80,000Source | 50,000Source | 61,000Source | 55,000Source | 949,000Source | 244,000Source | — | — |
| Investment Income, InterestUSD | — | — | 1,000Source | 3,000Source | — | — | — | — | 1,000Source | 8,000Source | 82,000Source | 45,944Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,400,000Source | -2,895,000Source | -4,807,000Source | -1,895,000Source | -14,455,000Source | -3,705,000Source | -17,298,000Source | -19,791,000Source | -10,008,000Source | -17,748,062Source |
| Nonoperating Income (Expense)USD | — | — | -84,000Source | 32,000Source | -205,000Source | 1,224,000Source | 444,000Source | -180,000Source | -1,026,000Source | 1,852,000Source | — | 5,340,146Source |
| Operating ExpensesUSD | — | — | — | — | — | — | 15,758,000Source | 3,525,000Source | 17,275,000Source | 21,643,000Source | — | 23,088,208Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | -3,000Source | -19,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 1,090,000Source | 10,725,000Source | 11,815,000Source | 7,016,000Source | 25,193,991Source |
| Restructuring CostsUSD | — | — | — | 83,000Source | — | — | — | — | — | 1,723,000Source | — | — |
| Gain (Loss) on Derivative Instruments, Net, Pretax | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | 1,975,000Source | 1,709,000Source | 2,525,000Source | 2,452,000Source | 2,169,000Source | 2,712,000Source | 9,280,000Source | 9,664,000Source | 11,356,000Source | 13,527,311Source |
| Operating Income (Loss)USD | — | — | -7,404,000Source | -2,927,000Source | -4,602,000Source | -3,119,000Source | -15,758,000Source | -3,525,000Source | -17,275,000Source | -21,643,000Source | -16,806,000Source | -23,088,208Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | -3,000Source | -19,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -7,488,000Source | -2,895,000Source | -4,807,000Source | -1,895,000Source | -15,314,000Source | -3,705,000Source | -18,301,000Source | -19,791,000Source | -10,008Source | -17,748,062Source |
| Income Tax Expense (Benefit)USD | — | — | -1,088,000Source | — | — | 0Source | -859,000Source | 0Source | -1,003,000Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -6,400,000Source | -2,895,000Source | -4,807,000Source | -1,895,000Source | -14,455,000Source | -3,705,000Source | -17,298,000Source | -19,791,000Source | -10,008,000Source | -17,748,062Source |
| Earnings Per Share, BasicUSD per share | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 65,326,236,698Source | 24,386,005,523Source | 143,317,469,445Source | 62,943,895,665Source | 118,757,013,401Source | 54,588,283,841Source | 67,328,128,638Source | 23,888,010,485Source | 9,788,980,193Source | 6,243,462,410Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 65,326,236,698Source | 24,386,005,523Source | 143,317,469,445Source | 62,943,895,665Source | 118,757,013,401Source | 54,588,283,841Source | 67,328,128,638Source | 23,888,010,485Source | 9,788,980,193Source | 6,243,462,410Source |
| Interest Expense (non-operating)USD | — | — | 121,000Source | 69,000Source | 80,000Source | 50,000Source | 61,000Source | 55,000Source | 949,000Source | 244,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Business Combination, Acquisition Related CostsUSD | — | — | — | 992,000Source | — | — | — | — | — | 3,273,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | 15,000Source | 27,000Source | 99,000Source | — | 255,000Source | 334,168Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | 76,000Source | 68,000Source | -26,000Source | -50,000Source | 64,000Source | -125,000Source | -443,000Source | 6,000Source | 136,000Source | 452,664Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 8,430,000Source | — | 0Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -19,678,000Source | -19,424,000Source | -10,267Source | -18,017,916Source |
| Interest ExpenseUSD | — | — | 100,000Source | — | — | — | — | — | 100,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 1,000Source | 3,000Source | — | — | — | — | 1,000Source | 8,000Source | 82,000Source | 45,944Source |
| Nonoperating Income (Expense)USD | — | — | -84,000Source | 32,000Source | -205,000Source | 1,224,000Source | 444,000Source | -180,000Source | -1,026,000Source | 1,852,000Source | — | 5,340,146Source |
| Operating ExpensesUSD | — | — | — | — | — | — | 15,758,000Source | 3,525,000Source | 17,275,000Source | 21,643,000Source | — | 23,088,208Source |
| Research and Development ExpenseUSD | — | — | 249,000Source | 143,000Source | 2,077,000Source | 667,000Source | 1,459,000Source | 813,000Source | 2,815,000Source | 6,983,000Source | 5,450,000Source | 9,560,897Source |
| Restructuring CostsUSD | — | — | — | 83,000Source | — | — | — | — | — | 1,723,000Source | — | — |
| Gain (Loss) on Derivative Instruments, Net, Pretax | — | — | — | — | — | — | —Source | — | — | — | — | — |
Offerings
Registration 333-297257
Registration 333-289962
Registration 333-295729
Registration 333-292930
Registration 333-291596
Filing attachments
ex107.htm · S-8 · 2026-10-30
Calculation of Filing Fee Tables S-8 Akari Therapeutics Plc ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount o…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-13
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated pancreatic cancer models Strategic research collaboration …
Read attachment ↗ex4-8.htm · S-3/A · 2026-07-08
Exhibit 4.8 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗ex4-9.htm · S-3/A · 2026-07-08
Exhibit 4.9 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗ex107.htm · S-3 · 2026-07-02
Calculation of Filing Fee Tables S-3 Akari Therapeutics Plc ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Off…
Read attachment ↗ex4-10.htm · S-3 · 2026-07-02
Exhibit 4.10 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANS…
Read attachment ↗